Teva Announces FDA Approval And Commercial Launch Of Fentanyl Transdermal System

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company’s Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the AB-rated generic equivalent of Ortho McNeil’s chronic pain treatment Duragesic®. Shipment of this product has commenced.

More: continued here

Filed under: Pain / Anesthetics on October 27th, 2008